Epithelioid mesothelioma is an aggressive cancer of the lining of the chest or abdomen. It is most commonly caused by asbestos exposure and is notoriously difficult to diagnose. However, advances in imaging techniques, pathology testing, and biomarkers research are providing new options for diagnosing epithelioid mesothelioma earlier and more accurately.
One of the key features of diagnosing epithelioid mesothelioma is the use of imaging tests. These tests can reveal the location and extent of the tumor, as well as the presence of other signs of mesothelioma, such as fluid in the chest or abdomen. Computed tomography (CT) scans are one of the most commonly used imaging tests for mesothelioma and can provide very detailed images of the tumor. Magnetic resonance imaging (MRI) scans may also be used to evaluate the tumor and surrounding tissues.
Pathology testing is also important for diagnosing epithelioid mesothelioma. Samples of the tumor can be taken and analyzed to look for specific markers that are associated with mesothelioma. These markers can help doctors make an accurate diagnosis. Immunohistochemistry (IHC) is one of the most commonly used pathology tests for mesothelioma and can help detect the presence of certain proteins and other molecules that are associated with the cancer.
In recent years, researchers have also been looking into the use of biomarkers to diagnose epithelioid mesothelioma. Biomarkers are molecules in the body that can be used to indicate the presence of a disease. There are several biomarkers that are associated with mesothelioma, such as mesothelin and calretinin. These biomarkers can be measured in blood or tissue samples and can be used to make a more accurate diagnosis.
Overall, advances in imaging techniques, pathology testing, and biomarkers research are helping to improve diagnosis of epithelioid mesothelioma. These new techniques are allowing for earlier detection of the disease, which can lead to better outcomes for patients.